91092-94-3

Basic information

• Product Name: (2E,4E)-5-(2-nitrophenyl)penta-2,4-dienoic acid
• CAS NO: 91092-94-3
• Molecular Formula: C₁₁H₉NO₄
• Molecular Weight: 219.1935
• Mol File: 91092-94-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 448.1°C at 760 mmHg
• Flash Point: 196.2°C
• Density: 1.34g/cm³
• Vapor Pressure: 8.18E-09mmHg at 25°C
• Refractive Index: 1.649
• CAS DataBase Reference: (2E,4E)-5-(2-nitrophenyl)penta-2,4-dienoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2E,4E)-5-(2-nitrophenyl)penta-2,4-dienoic acid(91092-94-3)
• EPA Substance Registry System: (2E,4E)-5-(2-nitrophenyl)penta-2,4-dienoic acid(91092-94-3)

Safety Data

• Hazardous Substances Data: 91092-94-3(Hazardous Substances Data)

Usage

Description

(2E,4E)-5-(2-nitrophenyl)penta-2,4-dienoic acid is a chemical compound that features a nitrophenyl group attached to a penta-2,4-dienoic acid structure. This organic compound is known for its unique properties and potential biological activity, making it a valuable component in scientific research and pharmaceutical applications.

Uses

Used in Medicinal Chemistry:
(2E,4E)-5-(2-nitrophenyl)penta-2,4-dienoic acid is used as a key component in the development of new drugs, leveraging its specific chemical and physical properties to enhance drug efficacy and target specific biological pathways.
Used in Organic Synthesis:
In the field of organic synthesis, (2E,4E)-5-(2-nitrophenyl)penta-2,4-dienoic acid serves as a versatile reagent, contributing to the creation of a wide range of chemical compounds for various scientific and industrial purposes.
Used in Scientific Research:
(2E,4E)-5-(2-nitrophenyl)penta-2,4-dienoic acid is utilized in scientific research to explore its potential biological activity and to understand its interactions with other molecules, which can lead to advancements in various fields of study.

Upstream product

• 133505-27-8 (2E,4E)-ethyl 5-(2-nitrophenyl)penta-2,4-dienoate 
• 1466-88-2 2-nitrocinnamic aldehyde 
• 141-82-2 malonic acid 
• 100610-33-1 2-nitro-trans-cinnamaldehyde diethylacetal 
• 552-89-6 2-nitro-benzaldehyde 
• 104-55-2 3-phenyl-propenal 

Downstream Products

• 406725-14-2 (2E,4E)-6-[5-(2-Nitrophenyl)penta-2,4-dienoylamino]hexanoic acid methyl ester 
• 103986-09-0 5t-(2-amino-phenyl)-penta-2t,4-dienoic acid 

Relevant articles and documents

Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo

Protease activated receptors (PARs) or thrombin receptors constitute a class of G-protein-coupled receptors (GPCRs) implicated in the activation of many physiological mechanisms. Thus, thrombin activates many cell types such as vascular smooth muscle cells, leukocytes, endothelial cells, and platelets via activation of these receptors. In humans, thrombin-induced platelet aggregation is mediated by one subtype of these receptors, termed PAR1. This article describes the discovery of new antagonists of these receptors and more specifically two compounds: 2-[5-oxo-5-(4-pyridin-2-ylpiperazin-1-yl)penta-1,3- dienyl]benzonitrile 36 (F 16618) and 3-(2-chlorophenyl)-1-[4-(4-fluorobenzyl) piperazin-1-yl]propenone 39 (F 16357), obtained after optimization. Both compounds are able to inhibit SFLLR-induced human platelet aggregation and display antithrombotic activity in an arteriovenous shunt model in the rat after iv or oral administration. Furthermore, these compounds are devoid of bleeding side effects often observed with other types of antiplatelet drugs, which constitutes a promising advantage for this new class of antithrombotic agents. 2009 American Chemical Society.

Carbamic acid compounds comprising an amide linkage as hdac inhibitors

This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.